Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 5% VVN001 ophthalmic solution for dry eye disease in China
CTR20241098Phase 3Active
- Sponsor
- VivaVision Biotech
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of VVN001 in dry eye syndrome (DED), sponsored by VivaVision Biotech. Started Apr 2024; status: active.
02
Drugs
VVN001
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20241098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241098.